論文・技術情報追加のお知らせ

1. A Real-World Disproportionality Analysis of Histamine H2-Receptors Antagonists (Famotidine): A Pharmacovigilance Study Based on Spontaneous Reports in the FDA Adverse Event Reporting System.

ファモチジンの未報告副作用に関する新たなシグナル

対象DB：FAERS

2. Real-world safety of maribavir: a retrospective study based on signal detection in the FDA adverse event reporting system.

マリビビルの副作用に関する新たなシグナルが発見

対象DB：FAERS

3. Hepatic adverse events associated with ketamine and esketamine: A population-based disproportionality analysis.

ケタミンとエスケタミンにおいて肝臓障害の報告が不均衡

対象DB：FAERS

4. Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events.

ロジグリタゾンがピオグリタゾンのシグナル検出に影響

対象DB：CVAR,FAERS

5. Romosozumab adverse event profile: a pharmacovigilance analysis based on the FDA Adverse Event Reporting System (FAERS) from 2019 to 2023.

ロモソズマブに関連する副作用の新たなシグナル

対象DB：FAERS

6. A Comprehensive Study on Adverse Reactions of Benzoyl Peroxide (BPO) in Dermatological Aesthetics Utilizing the FAERS Database.

過酸化ベンゾイル使用に伴う皮膚反応と安全性

対象DB：FAERS

7. A retrospective analysis of medications associated with pityriasis rosea reported in the FDA adverse events reporting system.

薬剤が引き起こす皮膚疾患「紅斑型乾癬」とその関連薬

対象DB：FAERS

8. Drug use and acute kidney injury: a Drug-Wide Association Study (DWAS) in Denmark and Sweden.

急性腎障害と関連する薬剤に関する研究

対象DB：FAERS

9. Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database.

ギルテリチニブとミドスタウリンの副作用に関する解析

対象DB：FAERS

10. Unveiling the safety profile of lecanemab: A comprehensive analysis of adverse events using FDA adverse event reporting system data.

レカネマブは神経系障害と画像異常を示す

対象DB：FAERS

11. Sexual dysfunctions associated with antipsychotic drug intake: a retrospective analysis of the FDA adverse events reporting system (FAERS).

抗精神病薬による性機能障害の報告、特にジプラシドン、アリピプラゾールが高リスク

対象DB：FAERS

12. Drug classes associated with the development of fulminant type 1 diabetes: a retrospective analysis using the FDA adverse event reporting system database.

FT1DMと関連する薬剤を特定、免疫療法薬等がリスク因子

対象DB：FAERS

13. Postmarketing safety evaluation of belimumab: a pharmacovigilance analysis.

ベリムマブの市販後安全性評価、新たな副作用も確認

対象DB：FAERS

14. Drug Interaction of SGLT2Is and ARNI on Acute Kidney Injury: A Real-World Pharmacovigilance Analysis Through the FAERS.

SGLT2阻害薬とARNIの併用がAKIのリスク増加と関連

対象DB：FAERS

15. Iodoform in Surgical Practice: A Comprehensive Review of Its Historical Evolution, Clinical Applications, and Safety Profiles.

ヨードフォームは外科で広く使われ、リスクも伴う

対象DB：JADER

16. Intradural extra-medullary spinal cord tumor after dorso-lumbar spine fixation following 12th dorsal vertebra burst fracture: A case report with literature review.

脊椎固定後にシュワノーマ発生、手術で改善

対象DB：JADER

17. Birth defects reporting and the use of dydrogesterone: a disproportionality analysis from the World Health Organization pharmacovigilance database (VigiBase).

ジドロゲステロン使用は先天性心疾患や陰茎異常の報告増加と関連

対象DB：VigiBase

18. A retrospective comparative study of percutaneous transhepatic gallbladder drainage versus endoscopic gallbladder stenting on the clinical course of acute cholecystitis: A propensity score matching analysis using a nationwide inpatient database in Japan.

胆嚢ドレナージ法は、PTGBDがEGBSより手術合併症リスクが低い可能性

対象DB：DPC

19. Clinical evaluation and outcome in heart failure patients receiving chemotherapy with different anti-cancer agents.

心不全患者への化学療法は再入院リスクを増加

対象DB：DPC

20. Differences in disease severity and in-hospital mortality in patients hospitalised for pneumonia with and without intellectual disabilities: A matched-pair retrospective cohort study using nationwide in-patient database.

知的障害(ID)は肺炎の重症度に関連

対象DB：DPC

21. Healthcare burden of narcolepsy in Japan: A retrospective analysis of health insurance claims from the Japan Medical Data Center.

ナルコレプシーは高い併存疾患負担、処方率、医療資源使用を伴う

対象DB：JMDC

22. Association between edaravone use and activities of daily living in older patients with atherothrombotic stroke: an observational study using Japanese real-world data.

エダラボンはアテロ型脳梗塞高齢者のADL改善に寄与

対象DB：MDV

23. Impact of 5-Aminosalicylic Acid on Ustekinumab in Inflammatory Bowel Disease: A Retrospective Medical Claims Analysis.

5-ASAとUST併用でCD/UCに有意な効果なし

対象DB：MDV

24. Prevalence and patient characteristics associated with cardiovascular disease risk factor screening in UK primary care for people with severe mental illness: an electronic healthcare record study.

SMI患者のCVDリスク検査は不十分

対象DB：CPRD

25. Diabetes complications in people with alcohol use disorder and type 2 diabetes.

AUD合併T2DMは合併症リスクが倍増

対象DB：CPRD

26. Estimating the burden of underdiagnosis within England: A modelling study of linked primary care data.

未診断率は疾患・地域で異なり、不均一

対象DB：CPRD

27. Impact of the COVID-19 pandemic on primary care for hypertension in the UK: a population-based cohort study.

COVID-19で高血圧診断・管理が大幅減少

対象DB：CPRD

28. Potential interactions between antimicrobials and direct oral anticoagulants: population-based cohort and case-crossover study.

DOACと抗菌薬併用で出血リスク増加なし

対象DB：CPRD

29. Burden of vascular risk factors by age, sex, ethnicity and deprivation in young adults with and without newly diagnosed type 2 diabetes.

早発2型糖尿病は全層で血管リスク増大

対象DB：CPRD

30. A UK population-based case-control study of blood tests before cancer diagnosis in patients with non-specific abdominal symptoms.

血液検査異常はがんの早期兆候で、迅速診断に有用

対象DB：CPRD

31. Lactic acidosis with metformin accumulation in the intensive care units of the Nord Pas de Calais region: A known serious adverse event that can be better prevented.

MALAは脱水や感染が誘因で発生し、予防可能例が多い。医師・患者教育が重要

対象DB：FPVD

32. Prevalence, Patient Characteristics, and Treatment of Patients with Hypertrophic Cardiomyopathy: A Nationwide Payer Database Study.

HCMの有病率は増加し、高齢者に多く、β遮断薬が主流で、精神疾患も多い

対象DB：DeSC